By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gloucester Pharmaceuticals, Inc. 

One Broadway, Suite 600

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-621-1561 Fax: 617-577-1209



Company News
Celgene (CELG) Completes Acquisition of Gloucester Pharmaceuticals, Inc. 1/15/2010 9:19:23 AM
Gloucester Pharmaceuticals, Inc. Presents ISTODAX(R) Data Demonstrating Clinical Benefit in Patients with CTCL Including Blood Involvement at American Society of Hematology Annual Meeting 12/7/2009 10:20:04 AM
Celgene (CELG) (JOBS) to Buy Gloucester Pharmaceuticals, Inc. in Cancer Drug Deal; Celgene to Pay $340 Million in Cash, $300 Million in Milestones 12/7/2009 6:52:58 AM
Gloucester Pharmaceuticals, Inc. Release: ISTODAX(R) Incorporated Into National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology(TM) for the Treatment of Cutaneous T-cell Lymphoma (CTCL) 12/3/2009 12:32:09 PM
Gloucester Pharmaceuticals, Inc. to Present Positive Results from Multiple Studies of ISTODAX(R) at the American Society of Hematology Annual Meeting 11/25/2009 9:15:16 AM
FDA Approves Gloucester Pharmaceuticals, Inc.'s ISTODAX(R) for Patients with Cutaneous T-cell Lymphoma 11/6/2009 7:01:28 AM
FDA Advisory Committee Recommends Gloucester Pharmaceuticals, Inc.'s Romidepsin for Approval for Cutaneous T-cell Lymphoma 9/2/2009 1:53:42 PM
Gloucester Pharmaceuticals, Inc. Gears Up for FDA Panel Vote on Lymphoma Drug 9/2/2009 7:43:29 AM
Gloucester Pharmaceuticals, Inc. Completes $29 Million Financing 8/25/2009 6:56:11 AM
Gloucester Pharmaceuticals, Inc. Announces FDA Advisory Committee Meeting to Discuss Romidepsin New Drug Application 8/17/2009 9:18:14 AM